These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 3058137)

  • 1. Importance of residual insulin secretion in type 1 diabetes.
    Skyler JS
    Lancet Diabetes Endocrinol; 2023 Jul; 11(7):443-444. PubMed ID: 37290467
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of FK 506 in new-onset type I diabetes in man.
    Carroll PB; Tzakis AG; Ricordi C; Rilo HR; Abu-Elmagd K; Murase N; Zeng YJ; Alejandro R; Mintz D; Starzl TE
    Transplant Proc; 1991 Dec; 23(6):3351-3. PubMed ID: 1721458
    [No Abstract]   [Full Text] [Related]  

  • 3. Different effect of two immunomodulating agents cyclosporin A and ciamexon on the insulin metabolism of cultured mouse islets.
    Linn T; Germann H; Bretzel RG; Helmke K; Bicker U; Federlin K
    Diabetes Res; 1987 Mar; 4(3):121-3. PubMed ID: 3038453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the immunomodulant 2-cyanaziridine derivative BM 41.332 on adjuvant arthritis in the rat.
    Bicker U
    Arzneimittelforschung; 1982; 32(7):746-52. PubMed ID: 6889876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
    Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciamexon in the low dose streptozotocin induced diabetes of mice.
    Linn T; Volkmann A; Germann H; Woehrle M; Bretzel RG; Bicker U; Federlin K
    Diabetes Res; 1987 Nov; 6(3):113-7. PubMed ID: 3325216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciamexon-treatment in endocrine ophthalmopathy.
    Utech C; Wulle KG; Pfannenstiel P; Adam W
    Acta Endocrinol Suppl (Copenh); 1987; 281():342-3. PubMed ID: 3303793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of ciamexon on blood glucose and insulin requirement in newly manifested type I diabetics. Results of a pilot study.
    Hogan M; Beyer J; Stuermer W; Weber P; Schrezenmeier J
    Arzneimittelforschung; 1988 Aug; 38(8):1185-9. PubMed ID: 3058137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Insulin therapy in 1984].
    Grimaldi A
    Ann Med Interne (Paris); 1984; 135(3):217-34. PubMed ID: 6378010
    [No Abstract]   [Full Text] [Related]  

  • 10. C-peptide: an index of insulin secretion.
    Faber OK; Binder C
    Diabetes Metab Rev; 1986; 2(3-4):331-45. PubMed ID: 3527619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Initial remission period in insulin-dependent diabetes in the young subject].
    Vague P; Vialettes B; Lassmann V; Moulin JP
    Diabete Metab; 1985 Jun; 11(3):181-8. PubMed ID: 3928412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The period of initial remission in insulin-dependent diabetes. Effect of optimized insulin therapy].
    Vague P; Vialettes B; Lassmann V; Moulin JP
    Journ Annu Diabetol Hotel Dieu; 1984; ():73-84. PubMed ID: 6399541
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.